- Global Pharma News & Resources

Down Syndrome Market Insights, Epidemiology and Market Forecast, 2027 Featuring Eisai, Transition Therapeutics Ireland, Balance Therapeutics & AC Immune

Down Syndrome Market Insights, Epidemiology and Market Forecast, 2027 Featuring Eisai, Transition Therapeutics Ireland, Balance Therapeutics & AC Immune

PR Newswire

DUBLIN, Oct 30, 2018

DUBLIN, Oct 30, 2018 /PRNewswire/ --

The "Down Syndrome - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to's offering.

Down Syndrome - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Down Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Down syndrome from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Down syndrome - Disease Understanding and Treatment Algorithm

The Down Syndrome market report gives the thorough understanding of the Down syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Down syndrome in the US, Europe, and Japan.

Down syndrome Epidemiology

The Down syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by gender- specific [Male and Female] and type specific [Trisomy 21, Mosaicism and Translocation] and diagnosed prevalent population of Down syndrome by clinical manifestation (Congenital heart disease, Ophalmologic complication, Neurological disorder, Hematologic - transient myeloproliferative disorder, Gastro intestinal, Otolaryngology, Endocrinlogy and Others).

According to this research, the prevalent cases of Down syndrome was 541,538 in 2016 in 7 MM and, is expected to increase during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of Down syndrome with 258,502 prevalent cases in 2016. In 7MM, males had highest prevalent cases of DS as compared to females in 2016. This trend is expected to increase during the study period

Down syndrome Drug Chapters

This segment of the Down syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. This report includes detailed chapters of promising upcoming therapies.

Down syndrome Market Outlook

The Down syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Down syndrome market is expected to grow during the forecasted period of 2018-2027 owing to the launch of few drugs (presently in Phase III and Phase II). Down syndrome therapeutics market has seen a 7MM sales of USD 1621.40 Million in 2016.

Down syndrome Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Down syndrome Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Down syndrome Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Down syndrome Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Down syndrome market
  • Organize sales and marketing efforts by identifying the best opportunities for Down syndrome market
  • To understand the future market competition in the Down syndrome market.

Companies Mentioned

  • Eisai
  • Transition Therapeutics Ireland Limited
  • Balance Therapeutics
  • AC Immune

For more information about this drug pipelines report visit

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


View original content:

SOURCE Research and Markets

Editor Details

Last Updated: 30-Oct-2018